MedTech Global Insights

This week on MedTech Global Insights, we dissect the FDA's aggressive new enforcement on medical device cybersecurity. As regulators begin to treat digital vulnerabilities as critical safety failures, the rules for market access have fundamentally changed. We explore what this means for manufacturers, from new pre-market submission requirements to the severe consequences of post-market negligence....

This week, we dissect the FDA's newly released guidance on General Wellness and Clinical Decision Support software. This isn't just a minor update; it's a critical clarification that redraws the line between a simple health app and a regulated medical device, forcing many developers to re-evaluate their entire business strategy. MedTech Global Insights explores the direct impact of these changes....

This week, we dissect the FDA's bombshell draft guidance on AI/ML-enabled medical devices. The new framework for Predetermined Change Control Plans (PCCPs) promises faster innovation but hides a complex web of new requirements. This episode unpacks what this means for manufacturers, from agile startups to global giants, and analyzes the strategic pivot required to leverage this new pathway instead...

The U.S. FDA has just escalated cybersecurity from a guideline to a mandatory gateway for market access. This episode of MedTech Global Insights unpacks the finalized guidance and its immediate, seismic impact on manufacturers of connected medical devices worldwide. We explore the immense operational challenges of new requirements like the Software Bill of Materials (SBOM) and proactive post-marke...

This week, we dissect the FDA's aggressive new stance on medical device cybersecurity, a shift causing major disruptions for manufacturers. What was once a recommendation is now a strict mandate, making cybersecurity documentation a primary reason for submission rejections and costly market entry delays. We explore how this regulatory crackdown moves beyond simple compliance to demand a proactive,...

This week on MedTech Global Insights, we dissect the UK MHRA's groundbreaking new accelerated approval pathway for AI-powered medical devices. This policy shift aims to make post-Brexit Britain a hub for digital health innovation, but what does it really mean for manufacturers on the ground? We explore the real-world implications through the lens of the first company to navigate this new process....

The European Union's notoriously complex MDR and IVDR regulations have been a major challenge for the MedTech industry. Last week, the European Commission unveiled a proposal to simplify the rules, offering a glimmer of hope for manufacturers. However, the situation is complicated by a new position paper from the Notified Bodies (Team-NB), who are raising concerns about the proposed changes. This...

Many MedTech companies breathe a sigh of relief after achieving their European CE mark, believing the hardest part is over. But a recent guidance document from the EU's Medical Device Coordination Group (MDCG) on post-market surveillance is proving that the finish line has moved. This new interpretation demands a more dynamic and data-intensive approach to monitoring devices, catching many manufac...

The FDA has finalized its groundbreaking rule, ending its long-standing enforcement discretion for Laboratory Developed Tests (LDTs). This episode unpacks this monumental shift, explaining how thousands of clinical laboratories across the United States will now fall under full medical device regulations, fundamentally changing the diagnostics landscape. We break down the four-year, five-stage tran...

This week, we dissect the massive $3.7 billion acquisition of Axonics by Boston Scientific. This deal, announced during the landmark J.P. Morgan Healthcare Conference, signals a major shift in the MedTech M&A landscape and sets a new competitive dynamic in the sacral neuromodulation market. We explore the strategic thinking behind the acquisition, analyzing why Axonics became such an attractive ta...

The U.S. FDA just launched the TEMPO pilot program, a groundbreaking "regulatory-light" pathway for digital health devices. This episode of MedTech Global Insights unpacks what this major shift means for manufacturers, how it ties regulatory approval directly to reimbursement, and why the game is changing for chronic disease management technologies. We look at the case of Ceribell, a company that...

In this episode of MedTech Global Insights, we dissect two monumental shifts in the U.S. regulatory landscape happening right now. The FDA is rolling out its new TEMPO pilot program, offering a potential "regulatory light" pathway for digital health technologies. This could revolutionize market access for AI, machine learning, and chronic disease management devices. However, this opportunity is on...

Last week, the US FDA announced a major shift in policy, easing regulations for low-risk digital health products and wearables. This move, revealed at CES 2026, aims to spur innovation by removing barriers for technologies that 'simply provide information' for general wellness. But this new freedom comes with a hidden challenge. The line between an unregulated wellness device and a regulated medic...

The promise of AI in medical devices is immense, but new guidance from US and European authorities reveals a widening gap in regulatory expectations. This episode of MedTech Global Insights breaks down the critical differences in how the FDA and EU handle AI device updates and what this means for your global strategy. We explore the practical impact of the FDA's flexible framework versus the EU's...

In the first week of January 2026, the FDA activated a new, mandatory cybersecurity rule, fundamentally changing the requirements for U.S. market access. This episode of MedTech Global Insights unpacks the immediate impact of this regulation, focusing on the challenging new requirement for a Software Bill of Materials (SBOM) and robust post-market surveillance plans. We explore what this means for...

In this episode, we dissect the U.S. FDA's landmark decision from the first week of January 2026 to ease regulations on general wellness and digital health wearables. This policy shift is set to accelerate innovation in the consumer health tech market but introduces a razor-thin line between being an unregulated gadget and a regulated medical device. We explore how a single marketing claim can com...

This week, we dissect a critical trend impacting the US MedTech landscape: the sustained surge in FDA warning letters. This isn't a random enforcement spike; it's a targeted campaign against systemic weaknesses in Quality Management Systems that many companies mistakenly believe are compliant. We move beyond the headlines to reveal the specific failures in CAPA and complaint handling that are putt...

This week, we dissect a critical, under-the-radar policy shift from the US FDA concerning AI and machine learning medical devices. Regulators are cracking down on Predetermined Change Control Plans (PCCPs), demanding a level of detail that many companies are unprepared for. This change fundamentally alters the roadmap for getting self-improving algorithms to market. We explore the new requirements...

This week, MedTech Global Insights dives into the US FDA's groundbreaking new final guidance on Predetermined Change Control Plans (PCCPs) for AI-enabled medical devices. This policy promises to accelerate innovation by allowing pre-approval for future algorithm updates, but it also introduces significant strategic complexities that could trap unprepared companies. We explore what this means for t...

In this episode, we dissect the recent FDA De Novo approval of a revolutionary AI diagnostic tool for oncology. While the industry celebrates this milestone, we look beyond the headlines to uncover the complex and demanding post-market challenges that await, from stringent real-world data collection to cybersecurity vigilance. Imagine a startup that poured all its resources into achieving this lan...

This week, MedTech Global Insights dives into the FDA's game-changing final rule to regulate Laboratory Developed Tests (LDTs) as medical devices. We unpack the agency's rationale behind this historic policy shift, ending decades of enforcement discretion that allowed thousands of labs to develop tests without direct FDA oversight. This episode explores the profound impact on innovation, patient s...

The FDA just dropped a bombshell on the AI medical device world. On January 2nd, they unveiled the 'AI-Driven SaMD Pre-Certification Excellence Program,' or AIPEP. This new pilot program promises a fast track for AI-powered software, but it comes with a catch: a mountain of new requirements for data transparency and algorithm validation. This move could reshape the competitive landscape, creating...

In the final days of 2025, the U.S. FDA unveiled a pivotal shift in policy, now allowing broader use of Real-World Data (RWD) in medical device submissions. This episode of MedTech Global Insights unpacks what this means for the industry, from startups to global enterprises. We explore the immense opportunities this presents for accelerating innovation and improving post-market surveillance. This...

In the final days of 2025, the medical device world felt the full force of the U.S. FDA's new cybersecurity mandate. With the 'Refuse to Accept' policy now in effect, the agency is turning away submissions that fail to meet stringent new security requirements before they are even reviewed. This is not a minor checklist item; it's a fundamental shift in how devices are designed, developed, and main...

In the final days of 2025, EU regulators issued a surprise mandate that reshapes the landscape for AI-driven medical devices. A new guidance requires the use of Real-World Evidence (RWE) for continuous, post-market validation of AI/ML algorithms, impacting all companies planning to enter or remain in the European market. This episode of MedTech Global Insights breaks down what this means for your...